益髓升白方对广泛期SCLC化疗所致的白细胞或中性粒细胞减少临床观察

Clinical Observation of Yisui Shengbaifang on Chemotherapy-Induced Neutropenia Caused by Extensive-Stage SCLC Chemotherapy

摘要: 目的：观察益髓升白方对广泛期小细胞肺癌患者一线化疗所致白细胞或中性粒细胞减少的影响。方法：选取2024年3月至2025年3月潍坊市益都中心医院肿瘤科收治的广泛期小细胞肺癌一线化疗患者40例，根据随机数表法分为两组各20例，对照组给予EP/EC方案化疗，治疗组在对照组的基础上自化疗后开始口服益髓升白膏方。最后比较两组患者化疗前、化疗后第7天的外周血白细胞数(WBC)、中性粒细胞计数(NE)及治疗前后的KPS评分、中医证候积分情况。结果：治疗后，两组患者的白细胞数及中性粒细胞计数较治疗前下降，研究组患者外周血白细胞数(WBC)及中性粒细胞计数(NE)较对照组呈现获益趋势，组间比较差异有统计学意义(P < 0.05)。经治疗后，两组患者的KPS功能状态评分均较治疗前获得明显改善，且实验组的KPS评分改善情况优于对照组。经统计学检验，两组差异具有统计学意义(P < 0.05)。而在中医证候改善方面，治疗后两组患者的证候积分均较治疗前下降，且实验组的证候积分下降程度明显优于对照组，组间差异具有统计学意义(P < 0.05)。结论：益髓升白方可有效改善小细胞肺癌化疗后骨髓抑制情况，且患者治疗后的体能状况评分更优、中医症候积分降低。

Abstract: Objective: To observe the effect of Yisui Shengbaifang (YS-SBF) on leukopenia or neutropenia induced by first-line chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). Methods: A total of 40 patients with ES-SCLC undergoing first-line chemotherapy admitted to the Department of Oncology of Weifang Yidu Central Hospital from March 2024 to March 2025 were selected. They were divided into two groups (n = 20 each) using a random number table method. The control group received EP/EC regimen chemotherapy. The treatment group received oral Yisui Shengbaifang paste in addition to the same chemotherapy regimen as the control group, starting after chemotherapy initiation. Peripheral blood white blood cell count (WBC), neutrophil count (NE) before and on day 7 after chemotherapy, as well as Karnofsky Performance Status (KPS) scores and Traditional Chinese Medicine (TCM) syndrome scores before and after treatment were compared between the two groups. Results: Following treatment, white blood cell (WBC) and neutrophil (NE) counts decreased in both patient groups compared to pre-treatment levels. A beneficial trend in peripheral blood WBC and NE counts was observed in the study group compared to the control group, with the intergroup difference being statistically significant (P < 0.05). After treatment, the Karnofsky Performance Status (KPS) scores improved significantly in both groups compared to baseline. The improvement in KPS scores was greater in the experimental group than in the control group, and this difference was statistically significant (P < 0.05). Regarding the improvement of Traditional Chinese Medicine (TCM) syndrome manifestations, the syndrome scores decreased in both groups after treatment compared to pre-treatment values. The reduction in syndrome scores was significantly greater in the experimental group than in the control group, and the intergroup difference was statistically significant (P < 0.05). Conclusion: Yisui Shengbaifang can effectively ameliorate chemotherapy-induced myelosuppression in patients with SCLC. Furthermore, patients receiving this treatment exhibited better performance status scores and lower TCM syndrome scores after treatment.